TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B.
Critical Path Institute's ® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle ...
Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled "Transforming Drug Development for Neurological Disorders: Proceedings from a ...
Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results